Bennett G Childs

This inventor holds 9 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research, Unity Biotechnology, Inc.. Active years: 2018-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bennett G Childs. Retrieved from https://idiyas.com/inventor/bennett-g-childs

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 9.5

ph-index = 4

Forward Citations = 44(Granted Patents)

Company Filing History:

9 out of 51

Buck Institute for Research on Aging

patents

9 out of 1,808

Mayo Foundation for Medical Education and Research

patents

9 out of 41

Unity Biotechnology, Inc.

patents

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12285427 - Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor (2025-04-29),

2. 11963957 - Treating cardiovascular disease by selectively eliminating senescent cells (2024-04-23),

3. 10517866 - Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor (2019-12-31),

4. 10478433 - Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss (2019-11-19),

5. 10478432 - Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye (2019-11-19),

6. 10413542 - Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinase (2019-09-17),

7. 10328073 - Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells (2019-06-25),

8. 10328058 - Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques (2019-06-25),

9. 10010546 - Treatment of ophthalmic conditions by selectively removing senescent cells from the eye (2018-07-03),

Title: Inventor Bennett G Childs - Pioneering Innovations in Rochester

Introduction: Bennett G Childs is a distinguished inventor based in Rochester, MN, known for his groundbreaking contributions to various fields.

Latest Patents: Bennett G Childs holds several patents in the areas of technology, healthcare, and consumer products, showcasing his versatility and ingenuity.

Career Highlights: Throughout his career, Bennett G Childs has demonstrated a keen ability to identify gaps in the market and develop innovative solutions to address them. His inventions have not only improved existing products but have also paved the way for new advancements in the industry.

Collaborations: Bennett G Childs has collaborated with leading companies, research institutions, and universities to bring his inventions to life. His collaborative spirit and dedication to excellence have earned him respect in the innovation community.

Conclusion: Bennett G Childs continues to push the boundaries of what is possible through his inventive spirit and commitment to creating a better future for all. His legacy as an inventor in Rochester, MN, will undoubtedly inspire future generations to pursue their innovative ideas.

Profile summary based on public USPTO records.